<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Prophylactic thyroidectomy in ethnic Chinese patients with multiple endocrine neoplasia type 2A syndrome after the introduction of genetic testing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Lau, GSK; Lang, BHH; Lo, CY; Tso, A; GarciaBarcelo, MM; Tam, PK; Lam, KSL</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>Hong Kong Medical Journal, 2009, v. 15 n. 5, p. 326-331</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2009</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/77074">http://hdl.handle.net/10722/77074</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>Hong Kong Medical Journal. Copyright © Hong Kong Medical Association.; This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
Prophylactic thyroidectomy in ethnic Chinese patients with multiple endocrine neoplasia type 2A syndrome after the introduction of genetic testing

Objective To evaluate the impact of genetic testing in the management of familial multiple endocrine neoplasia 2A patients.

Design Retrospective study.

Setting University teaching hospital, Hong Kong.

Patients Twenty-two patients from eight multiple endocrine neoplasia 2A families underwent prophylactic total thyroidectomy based on a positive RET mutation genetic testing. All mutations were located at codon 634 of exon 11. Nineteen patients had preoperative basal serum calcitonin measured, and the 12 with normal levels had pentagastrin stimulation tests. Preoperative thyroid ultrasound examination was performed for 17 patients.

Results There were 13 females and 9 males with a median age of 25.1 (range, 6.1-71.9) years. Histopathology revealed medullary thyroid carcinoma in 17 (77%), C-cell hyperplasia in four (18%), and normal pathology in one (5%) of the patients. Five patients with either C-cell hyperplasia or normal pathology were among the youngest (age range, 6-9 years). The youngest patient with medullary thyroid carcinoma was nearly 9 years old. The median size of medullary thyroid carcinomas was 8.3 (range, 0.1-18) mm, but there were no lymph node metastases. Of 15 patients with normal basal calcitonin levels, 10 had medullary thyroid carcinoma, though two tested negative with the pentagastrin-stimulated calcitonin assay. Five of six patients with normal preoperative ultrasonographic examinations had medullary thyroid carcinoma. Three (14%) of the patients were prescribed long-term calcium and vitamin D supplementation. After a median follow-up of 49 (range, 13-128) months, no patient had recurrence of medullary thyroid carcinoma.

Conclusions Genetic testing has replaced conventional biochemical and radiological modalities to identifying multiple endocrine neoplasia 2A carriers, in order to offer them prophylactic thyroidectomy. Chinese multiple endocrine neoplasia 2A patients with codon 634 mutation seem to have less aggressive forms of medullary thyroid carcinoma, for whom prophylactic thyroidectomy can be considered at the age of 8 years.

Introduction Multiple endocrine neoplasia type 2A (MEN2A) is an autosomal dominant disorder associated with the occurrence of medullary thyroid carcinoma (MTC), phaeochromocytoma and parathyroid hyperplasia. The penetrance is almost 100% for MTC while approximately 50% and 30% of patients will develop subsequent phaeochromocytomas and hyperparathyroidism, respectively.1,4

Medullary thyroid carcinoma remains a major cause of death in MEN2A patients.5 Before the introduction of genetic screening for the RET proto-oncogene, the diagnosis was usually delayed and led to frequent presence of nodal and distant metastases on presentation. Cancer-related mortality occurred in up to 15 to 20% of these patients.6,7 Moreover, biochemical surveillance based on stimulated calcitonin for early diagnosis was associated with false-negative and false-positive results. In addition, the test was unpleasant and troublesome and needed to be repeated regularly for all at-risk patients. With the
availability of accurate genetic testing, prophylactic thyroidectomy can now be offered to all asymptomatic RET proto-oncogene carriers.8-10 Furthermore, with a better understanding of the genotype-phenotype correlation, for ‘high-risk’ carriers with codon 611, 618, 620, or 634 mutations, it is now recommended that the operation should be offered as early as the age of 5 years.9,11 This advice was based on the fact that invasive MTC rarely developed earlier, but the recommendation provoked controversy because of the increased potential for surgical complications, parental concerns, and problems related to long-term drug compliance.12,13

Clinicopathological features of ethnic Chinese patients with MEN2A syndrome have been reported, but the impact of genetic testing and the recommendation for the optimal timing of prophylactic thyroidectomy have not been addressed.14,15

The present study aimed at reviewing our experience of prophylactic thyroidectomy in asymptomatic MEN2A carriers after the introduction of genetic testing for the RET proto-oncogene, and to make recommendations on the optimal age for prophylactic thyroidectomy for our Chinese MEN2A patients.

Methods

Subjects

Since 2005, a territory-wide registry for patients with hereditary endocrinopathy has been established at our institution. Patients from families with suspected or documented MEN2 syndrome were managed by a multidisciplinary team, including endocrine surgeons, endocrinologists, radiologists, endocrine pathologists, and clinical oncologists. All the patients were followed up in the special clinic at our institution and genetic testing was performed in our research laboratory. To date, our registry has identified a total of eight MEN2A families. Molecular testing for the RET germline mutation was performed in 79 at-risk or affected individuals from these families, after they had received genetic counselling; and 40 were confirmed to have a germline mutation in the RET proto-oncogene. Thyroidectomy was performed on a prophylactic basis for 22 genetic carriers who were completely asymptomatic and had no clinical evidence of MTC. They included 13 women and nine men. At the time of surgery, their median age was 25.1 years (range, 6.1-71.9) years.

Genetic testing

All patients and/or their legal guardians gave written consent, in accordance with the requirements of our institutional ethics committee. Blood samples were obtained from at-risk family members by peripheral veni-puncture. Genomic DNA was prepared from peripheral blood leukocytes by standard procedures, and RET mutations were screened for by restriction enzyme digestion and/or direct sequencing, as described previously.14

Preoperative evaluation and surgery

Before surgery, all confirmed RET mutation carriers were advised to undergo a complete physical examination, and measurement of basal and stimulated plasma calcitonin, as well as serum-adjusted calcium and parathyroid hormone levels. At least two samples of 24-hour urinary fractionated catecholamines were assayed for patients older than 16 years to rule out a concomitant phaeochromocytoma. Before the operation, ultrasonography (USG) of the thyroid gland was also recommended for all confirmed RET carriers. For those with biochemical or imaging evidence of MTC, in addition to ‘prophylactic’ total

遺傳檢測後為多發性內分泌腫瘤2A型的華籍患者進行預防性甲狀腺切除術

目的  檢討遺傳檢測對多發性內分泌腫瘤2A型患者的影響。

設計  回顧研究。

安排  香港一所大學教學醫院。

患者  本研究對象為接受RET原致癌基因檢查而呈陽性反應的22位多發性內分泌腫瘤2A型患者, 他們來自八個家庭, 並已接受預防性全甲狀腺切除術。所有患者的基本資料及基因突變位置均在exon 11的codon 634, 介乎6.1至71.9年。組織病理學顯示17人(77%)有甲狀腺髓質癌，其餘4人(18%)有C細胞增生，另1人(5%)屬正常；這裡5位是22位病人中最年青的(介乎6至9歲)。甲狀腺髓質癌患者中，年紀最小為9歲；髓質癌的大小中位數為8.3 mm (介乎0.1至18 mm)，沒有出現淋巴結轉移。15位有正常血降鈣素濃度的患者中，10位有甲狀腺髓質癌，縱然2位的五肽胃泌素激發測試結果呈陰性。6位甲狀腺超聲波檢查屬正常的病人中，5位有甲狀腺髓質癌。3位(14%)病人要長期服食鈣及維他命D補充劑。中位數為49個月(介乎13至128個月)的隨訪期內，沒有病人出現甲狀腺髓質復發。

結論  為了讓多發性內分泌腫瘤2A型的患者進行預防性甲狀腺切除術, 遺傳檢測已取代傳統的生化及放射性檢查方法。基因突變位置為codon 634的華籍患者, 似乎其多發性內分泌腫瘤都屬非惡性的, 這種情況下, 可考慮在當患者8歲時施行預防性甲狀腺切除術。
thyroidectomy; a unilateral central compartment (level VI) neck dissection was also performed.

Follow-up
All patients received lifelong thyroxine replacement after surgical treatment and were followed up regularly in our special clinic. Follow-up visits were arranged at 3-monthly interval in the first 2 years, 6 monthly for the subsequent 3 years, and annually thereafter. Clinical examinations, basal plasma calcitonin, serum calcium and thyroid function tests were performed during follow-up visits. A stimulated calcitonin assay was selectively repeated for those with abnormal findings before surgical treatment. Cervical USG was performed annually to look for potential local/regional recurrence. Patients with undetectable calcitonin levels and normal USG findings were regarded as disease-free. Postoperative hypoparathyroidism was regarded as permanent if calcium and/or vitamin D analogues were required to maintain normocalcaemia in the presence of subnormal or undetectable parathyroid hormone levels of more than 12 months after the operation.

Results
The Table shows the clinical, biochemical, and molecular features of the 22 RET proto-oncogene carriers who underwent prophylactic thyroidectomy based on positive genetic testing. All the RET mutations were located at codon 634. The specific identified RET mutations were as follows: C634Y (12 patients; 55%), C634R (4 patients; 18%), C634W (3 patients; 14%), and C634G (3 patients; 14%). Three (14%) patients were identified to have had phaeochromocytomas, and adrenalectomy was performed 3.8 years, 7 months, and 3 months before their prophylactic total thyroidectomy. One of these three patients had a malignant phaeochromocytoma extending to the right atrium and was previously reported. Two patients underwent concomitant parathyroidectomy at the time of prophylactic thyroidectomy because of hypercalcemia and parathyroid hyperplasia. One had a subtotal parathyroidectomy, while the other had a total parathyroidectomy and forearm

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age at operation (years)</th>
<th>RET mutation</th>
<th>Basal calcitonin (pmol/L)†</th>
<th>Peak calcitonin (pmol/L)</th>
<th>Positive SCT response</th>
<th>USG nodule</th>
<th>Histology</th>
<th>Lymph node metastasis</th>
<th>Calcium supplement</th>
<th>Follow-up period (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6.1</td>
<td>C634W</td>
<td>1.8</td>
<td>1.7</td>
<td>No</td>
<td>Yes</td>
<td>CCH</td>
<td>No</td>
<td>No</td>
<td>14</td>
</tr>
<tr>
<td>2</td>
<td>6.3</td>
<td>C634Y</td>
<td>1.6</td>
<td>1.8</td>
<td>No</td>
<td>Yes</td>
<td>CCH</td>
<td>0/2</td>
<td>Yes</td>
<td>13</td>
</tr>
<tr>
<td>3</td>
<td>7.1</td>
<td>C634Y</td>
<td>0.0</td>
<td>0.36</td>
<td>No</td>
<td>Yes</td>
<td>CCH</td>
<td>0/4</td>
<td>Yes</td>
<td>13</td>
</tr>
<tr>
<td>4</td>
<td>8.6</td>
<td>C634W</td>
<td>0.38</td>
<td>0.38</td>
<td>No</td>
<td>Yes</td>
<td>Normal</td>
<td>No</td>
<td>No</td>
<td>13</td>
</tr>
<tr>
<td>5</td>
<td>8.9</td>
<td>C634Y</td>
<td>1.1</td>
<td>1.5</td>
<td>No</td>
<td>No</td>
<td>CCH</td>
<td>0/2</td>
<td>No</td>
<td>13</td>
</tr>
<tr>
<td>6</td>
<td>8.6</td>
<td>C634R</td>
<td>3.1</td>
<td>35.0</td>
<td>Yes</td>
<td>No</td>
<td>MTC 0.1 mm</td>
<td>No</td>
<td>No</td>
<td>49</td>
</tr>
<tr>
<td>7</td>
<td>10.7</td>
<td>C634Y</td>
<td>4.1</td>
<td>4.6</td>
<td>No</td>
<td>-</td>
<td>MTC 3.4 mm</td>
<td>No</td>
<td>Yes</td>
<td>13</td>
</tr>
<tr>
<td>8</td>
<td>12.3</td>
<td>C634Y</td>
<td>1.2</td>
<td>2.9</td>
<td>No</td>
<td>No</td>
<td>MTC 1.8 mm</td>
<td>0/3</td>
<td>No</td>
<td>15</td>
</tr>
<tr>
<td>9</td>
<td>11.9</td>
<td>C634Y</td>
<td>-</td>
<td>-</td>
<td>Yes</td>
<td>-</td>
<td>MTC 5 mm</td>
<td>No</td>
<td>No</td>
<td>50</td>
</tr>
<tr>
<td>10</td>
<td>18.4</td>
<td>C634R</td>
<td>8.4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>MTC 12 mm</td>
<td>0/1</td>
<td>No</td>
<td>88</td>
</tr>
<tr>
<td>11</td>
<td>20.1</td>
<td>C634Y</td>
<td>0.44</td>
<td>6.5</td>
<td>Yes</td>
<td>No</td>
<td>MTC 15 mm</td>
<td>No</td>
<td>No</td>
<td>50</td>
</tr>
<tr>
<td>12</td>
<td>25.4</td>
<td>C634Y</td>
<td>1.6</td>
<td>-</td>
<td>-</td>
<td>No</td>
<td>MTC in-situ</td>
<td>0/5</td>
<td>No</td>
<td>14</td>
</tr>
<tr>
<td>13</td>
<td>28.0</td>
<td>C634G</td>
<td>0.5</td>
<td>44.0</td>
<td>Yes</td>
<td>No</td>
<td>MTC 0.1 mm</td>
<td>No</td>
<td>Yes</td>
<td>53</td>
</tr>
<tr>
<td>14</td>
<td>32.1</td>
<td>C634G</td>
<td>6.5</td>
<td>109.0</td>
<td>Yes</td>
<td>Yes</td>
<td>MTC 5 mm</td>
<td>0/3</td>
<td>Yes</td>
<td>101</td>
</tr>
<tr>
<td>15</td>
<td>33.1</td>
<td>C634G</td>
<td>1.1</td>
<td>53.0</td>
<td>Yes</td>
<td>Yes</td>
<td>MTC 3 mm</td>
<td>0/2</td>
<td>Yes</td>
<td>52</td>
</tr>
<tr>
<td>16</td>
<td>34.0</td>
<td>C634Y</td>
<td>122.0</td>
<td>3900.0</td>
<td>Yes</td>
<td>-</td>
<td>MTC 15 mm</td>
<td>No</td>
<td>No</td>
<td>48</td>
</tr>
<tr>
<td>17</td>
<td>34.8</td>
<td>C634Y</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>MTC 15 mm</td>
<td>No</td>
<td>No</td>
<td>128</td>
</tr>
<tr>
<td>18</td>
<td>41.0</td>
<td>C634R</td>
<td>4.0</td>
<td>72.0</td>
<td>Yes</td>
<td>Yes</td>
<td>MTC 4 mm</td>
<td>No</td>
<td>Yes</td>
<td>118</td>
</tr>
<tr>
<td>19</td>
<td>41.9</td>
<td>C634W</td>
<td>-</td>
<td>-</td>
<td>Yes</td>
<td>-</td>
<td>MTC 8 mm</td>
<td>0/17</td>
<td>No</td>
<td>45</td>
</tr>
<tr>
<td>20</td>
<td>41.4</td>
<td>C634Y</td>
<td>4.0</td>
<td>-</td>
<td>-</td>
<td>Yes</td>
<td>MTC 18 mm</td>
<td>No</td>
<td>Yes</td>
<td>56</td>
</tr>
<tr>
<td>21</td>
<td>50.7</td>
<td>C634Y</td>
<td>693.0</td>
<td>930.0</td>
<td>No</td>
<td>Yes</td>
<td>MTC 10 mm</td>
<td>0/3</td>
<td>No</td>
<td>57</td>
</tr>
<tr>
<td>22</td>
<td>71.9</td>
<td>C634R</td>
<td>4.9</td>
<td>-</td>
<td>Yes</td>
<td>-</td>
<td>MTC 8 mm</td>
<td>0/1</td>
<td>No</td>
<td>83</td>
</tr>
</tbody>
</table>

TABLE. The clinical, biochemical, and molecular features of the 22 asymptomatic multiple endocrine neoplasia type 2A patients who underwent prophylactic thyroidectomy

* SCT denotes stimulated calcitonin test, USG ultrasonography, CCH C-cell hyperplasia, and MTC medullary thyroid carcinoma
† Normal level: <6.0 pmol/L
Laboratory and ultrasonographic findings

Nineteen patients had preoperative plasma basal calcitonin measured, of whom 15 had normal levels. All four patients with an elevated basal calcitonin level had MTC, while 10 (67%) of 15 with normal basal calcitonin levels also had MTC. Five (33%) of the 15 patients with normal calcitonin levels had a positive calcium-pentagastrin test and an invasive MTC, whilst among the remaining seven with normal basal calcitonin level and negative calcium-pentagastrin test results, three had MTC on histological examination. Ultrasonography of the thyroid gland was performed in 17 patients. Five (83%) of six patients with a normal USG examination subsequently turned out to have MTC, as did seven of the 11 with one or more thyroid nodules detected preoperatively.

Thyroid gland pathology

Histological examination of the resected thyroid gland showed normal pathology in one (5%), C-cell hyperplasia in four (18%), and MTC in 17 (77%) patients. Twelve (55%) patients had concomitant C-cell hyperplasia associated with the invasive carcinoma. C-cell hyperplasia or a normal thyroid gland without invasive MTC was encountered in the five youngest patients, with a median age of 7.1 years (range, 6.1-8.9 years). The youngest patient with MTC identified was 8.6 years old. The mean MTC tumour size on histological section was 8.3 mm (range, 0.1-18 mm). Central lymph node dissection was performed in 11 (50%) of the 22 patients but none was found to have metastasis.

Surgical outcome and follow-up data

Postoperative laryngoscopic examination did not reveal any vocal cord paralysis. Eight patients developed postoperative hypocalcaemia for which both oral calcium and vitamin D supplementation was given, in three (14%) of whom the supplements became permanent. During a median follow-up of 49 months (range, 13-128 months), phaeochromocytoma was diagnosed in five of the patients through urinary screening of fractionated catecholamines, and after localisation with imaging they underwent adrenalectomy. In addition to the three patients who presented with phaeochromocytoma as their initial manifestation, five others developed phaeochromocytoma later during the course of their disease. At the time of analysis, two (9%) additional patients had mild hyperparathyroidism and were being managed expectantly. At 1-year follow-up, one paediatric patient had fluctuating thyroid function test results, despite good thyroxine compliance with replacement. After a median follow-up of 49 months, no patient had any clinical, biochemical, or ultrasonographic evidence of MTC recurrence.

Discussion

Invasive MTC invariably develops in all patients with MEN2A. Since these tumours tend to metastasise early and are both chemo- as well as radio-resistant, early prophylactic surgery remains the only curative option. Graze et al8 showed that selection of affected kindred for prophylactic thyroidectomy through identification by calcitonin testing alone resulted in discovery of primary tumours of smaller size (0.2 cm vs 0.8 cm), fewer bilateral tumours (13% vs 100%), and fewer patients with lymph node metastases (0% vs 58%). With recent introduction of RET proto-oncogene testing for the accurate identification of gene carriers, prophylactic thyroidectomy can be offered to asymptomatic affected individuals at the stage of pre-malignant C-cell hyperplasia before the histological occurrence of invasive MTC.

Our study confirmed that neither traditional biochemical tests with pentagastrin-stimulated calcitonin assay nor radiological imaging with USG could reliably predict the occurrence of invasive MTC. Two thirds (10/15) of the patients with normal preoperative basal calcitonin levels had MTC on final histology. Although the accuracy of the calcitonin assay improved with pentagastrin stimulation, three (20%) of the 15 patients with normal results harboured MTC in their thyroidectomy specimens. Preoperative USG imaging to identify invasive MTC was also inaccurate. Five (83%) of six patients with normal USG had MTC histologically. Even when combined with the pentagastrin-stimulated calcitonin assay, the false-negative rate remained at 50%, of which the finding was consistent with results reported from previous studies.

Although the role of RET proto-oncogene genetic testing to facilitate the identification of gene carriers for prophylactic surgery is not in dispute, the most appropriate timing for the operation remains controversial. Ideally it should be before the development of invasive MTC (at the stage of pre-malignant C-cell hyperplasia) and lymph node metastasis. Too early or overly aggressive surgical treatment, however, could be associated with an increased surgical morbidity and the issue of long-term drug compliance. A recent territory-wide multi-centre study reported by Bergenfelz et al highlighted these issues. They reported a 3.9% rate of vocal cord paresis, and 4.4% rate of hypocalcaemia for which the patients were receiving calcium and/or vitamin D supplements at 6 months. Also in a recent review of 41 MEN2A patients aged less than 25 years who underwent thyroidectomy, 29% had permanent hypoparathyroidism. In our
study, although none of the subjects suffered from postoperative vocal cord paresis, three (14%) of 22 had permanent hypocalcaemia, two of whom were among the youngest patients (<8 years). Further improvement in outcomes in terms of decreased incidence of hypocalcaemia in this growing age-group would be of benefit for patients undergoing prophylactic thyroidectomy. In terms of long-term drug administration and compliance, two of the nine patients below the age of 18 years had fluctuating thyroid function test results on follow-up, mostly with persistently elevated thyroid-stimulating hormone levels. In this age-group, the changing requirement of thyroxine during growth and development, as well as long-term compliance with thyroxine replacement, also needs further evaluation.

The application of ‘codon-directed’ guidelines for management of MEN2A patients apparently originated from the West. The objective of the present study was to identify any potential differences with respect to this genetic disease in our population. Based on the international consensus statement in 2001,11 all our 22 patients (with codon 634 mutation) belonged to the ‘high-risk’ group, for which surgery was recommended before the age of 5 years in order to avoid the occurrence of invasive MTC. In our series, the earliest age for positive identification of MTC development in our MEN2A patients was 8 years, while four other younger patients were confirmed to have either normal histology or C-cell hyperplasia. Based on our experience, and taking into consideration the problems emanating from surgery in very young patients as well as the need to take long-term thyroxine, it might be worth considering prophylactic thyroidectomy at the age of 8 rather than 5 years. In addition, despite the ‘prophylactic’ operation being performed in patients up to 71 years old and a tumour size of 1.8 cm (owing to genetic study at a delayed stage), none of our patients were identified to have lymph node metastases and all have remained free of disease till their latest follow-up. Our findings should be interpreted cautiously however, as the number of patients studied was relatively small, whilst in other populations undergoing prophylactic thyroidectomy, invasive MTC has been reported in patients as young as 17 months.4,12 In summary, although our ethnic Chinese MEN2A patients with codon 634 mutation appeared to be suffering from a less aggressive form of MTC, a prospective study involving a larger number of ethnic Chinese patients is required.

Conclusions

Genetic RET proto-oncogene testing has replaced traditional biochemical tests and imaging to facilitate decisions about prophylactic thyroidectomy in MEN2A families. To prevent the development of invasive MTC, our experience in the management of local MEN2A patients suggests resorting to prophylactic thyroidectomy for these children possibly at the age of 8 years or younger. The risk of permanent hypoparathyroidism and the issue of early long-term thyroid function and replacement therapy remain a concern in this group of young children.

Acknowledgement

The establishment of the territory-wide MEN registry was funded by the generosity of the SK Yee Medical Foundation.

References


